Paraneoplastic Syndromes

Chapter 11. Paraneoplastic Syndromes

Ruthanne Chun




Paraneoplastic syndromes (PNS) are systemic disorders resulting from substances produced by a tumor. According to the strictest definition, PNS are caused by the production and release of substances not normally produced by the tumor cell of origin or in amounts not normally produced by those cells. Hypoglycemia resulting from an insulinoma, hyperglobulinemia resulting from multiple myeloma, and hyperestrogenism resulting from testicular tumors are mentioned in this chapter because of their effects on multiple systems in the body. Pathologies caused by PNS, as opposed to the finding of a tumor, may be the factor that prompts the client to pursue veterinary attention. Other etiologies of PNS aside from production of metabolically active substances include autoimmune disease induction, immune complex formation, immunosuppression, and ectopic receptor production/competitive blockade of normal hormones. PNS may also arise because of substances produced by normal cells caused by presence of the tumor (e.g., tumor necrosis factor production contributing to cancer cachexia). Many PNS in veterinary medicine are of unknown etiology.

PNS are common in human cancer patients. The PNS may precede identification of the cancer by weeks to years. Thus, recognition of PNS is important for many reasons. A PNS may be the first sign of disease, facilitating work-up and diagnosis. Monitoring the PNS can be an effective means of evaluating response to anti-cancer therapy and tumor relapse.





























































































TABLE 11-1 SUMMARY OF PARANEOPLASTIC SYNDROMES, THE TUMORS WITH WHICH THEY ARE ASSOCIATED, THEIR SYSTEMIC EFFECT, AND FREQUENCY
CA , Carcinoma; HSA , hemangiosarcoma ; LSA , lymphoma; MM , multiple myeloma.
Paraneoplastic Syndrome Associated Tumor(s) Systemic Effect Frequency
Endocrinologic paraneoplastic syndromes
Hypercalcemia LSA, MM, thymoma, anal sac adenocarcinoma, parathyroid tumors, miscellaneous other Polyuria/polydipsia, renal failure, arrhythmias, seizures, coma, death Common
Hypoglycemia LSA, intestinal and hepatic tumors, insulinoma Behavioral changes, seizures, death Uncommon
Hyperestrogenism Testicular tumors Alopecia, gynecomastia, skin changes, pancytopenia Uncommon
Hematologic paraneoplastic syndromes
Anemia LSA, MM, thymoma, HSA Weakness, inappetence, or anorexia Common
Polycythemia Renal and nasal tumors Polydipsia, dark red mucous membranes, inappetence/anorexia, seizures, death Rare
Thrombocytopenia and coagulopathies HSA, LSA, MM, multiple others Petechiation, bleeding tendencies Common
Hyperglobulinemia LSA, MM Increased susceptibility to infection; hyperviscosity that is associated with heart failure, bleeding tendencies, renal failure, behavioral changes, seizures, polyuria Uncommon
Neutrophilic leukocytosis Renal tumors, HSA None Rare
Neurologic Paraneoplastic Syndromes
Myasthenia gravis, peripheral neuropathy LSA, thymoma, miscellaneous other Regurgitation, weakness, depends upon affected site Rare
Cutaneous Paraneoplastic Syndromes
Alopecia Pancreatic or biliary CA, thymoma—cats Easily epilated hair or alopecia Rare
Superficial necrolytic dermatitis Glucagonoma or glucagon-secreting tumors, liver CA, pancreatic CA—cats Alopecia, skin erosions and crusts, pad hyperkeratosis Rare
Miscellaneous Paraneoplastic Syndromes
Hypertrophic osteopathy Intrathoracic and intra-abdominal tumors Lameness (often shifting leg lameness), limb edema Uncommon
Fever Any Lethargy, anorexia Rare
Cachexia Any Weight loss and anorexia Rare


ENDOCRINOLOGIC PARANEOPLASTIC SYNDROMES


Hypercalcemia

Hypercalcemia of malignancy is most commonly caused by production of parathyroid hormone-related peptide (PTH-rp) by tumor cells. 1-3 It is most often associated with lymphoma, anal sac adenocarcinoma, multiple myeloma, thymoma, and, especially in cats, squamous cell carcinoma; however, many other tumors have been linked with hypercalcemia. 4-14 Hypercalcemia may also be caused by primary hyperparathyroidism and excessive production of parathyroid hormone (PTH). 1,2 Although serum 1,25-dihydroxycholecalciferol (calcitriol) plays a role in hypercalcemia of malignancy in people, it does not appear to play a significant role in veterinary patients. 15-18 Other differentials for hypercalcemia are listed in Box 11-1 . 19-21

BOX 11-1
NON-NEOPLASTIC DIFFERENTIAL DIAGNOSES FOR HYPERCALCEMIA 19-21






Laboratory error


Primary renal disease


Primary hyperparathyroidism


Hypervitaminosis D


Cholecalciferol rodenticides


Plant ingestion such as calcitrol glycosides


Iatrogenic


Hypervitaminosis A


Hemoconcentration


Hyperproteinemia


Skeletal lesions


Hypertrophic osteodystrophy


Osteomyelitis


Disuse osteoporosis


Factitious


Lipemia


Post-prandial samples


Young animal <6–12 mos


Thiazide diuretics


Granulomatous disease


Hypoadrenocorticism


Idiopathic hypercalcemia of cats

The most common clinical sign associated with this PNS is polyuria resulting from calcium interfering with renal tubule cell response to anti-diuretic hormone. Other signs may include polydipsia, inappetence, vomiting, weakness, bradycardia, obtundation, and death.


Therapy for hypercalcemia of malignancy is two-fold: treatment of the hypercalcemia if necessary and, more importantly, of the underlying malignancy. Animals with clinical signs of hypercalcemia beyond polyuria (e.g., weak, vomiting, bradycardic), typically those with total calcium ≥18 mg/dL, should be hospitalized and treated with aggressive fluid therapy using a calcium-replete solution (e.g., 0.9% NaCl at >66 ml/kg/day with urine output goal of 2 ml/kg/hr). Furosemide (2–4 mg/kg PO, SC, or IV bid) may be administered to promote calciuresis, provided the patient is well hydrated. Aside from serious clinical signs, other indications for treatment include a calcium phosphorus product (total calcium × phosphorus) ≥60. Other pharmacologic options for decreasing calcium include prednisone (1–2 mg/kg PO, SC, or IV bid), calcitonin (4-6 IU/kg SC bid to tid) or bisphosphonates. 22 The use of prednisone is ill-advised unless the patient has been screened for lymphoma, since steroid use may induce remission of this disease and can make subsequent diagnosis impossible. Calcitonin use may fall out of favor now that bisphosphonates are available and have been used in veterinary patients. Patients with unresolved hypercalcemia after saline-induced diuresis and furosemide should be treated with pamidronate at 1 mg/kg given over 2 hours in 250 ml 0.9% saline. 22,23 Effective treatment of the underlying malignancy is the approach most likely to resolve the hypercalcemia.

Stay updated, free articles. Join our Telegram channel

Jul 24, 2016 | Posted by in SMALL ANIMAL | Comments Off on Paraneoplastic Syndromes

Full access? Get Clinical Tree

Get Clinical Tree app for offline access